Prelude Therapeutics Incorporated (PRLD) vs Cartesian Therapeutics, Inc. (RNAC)
A side-by-side comparison of Prelude Therapeutics Incorporated and Cartesian Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PRLD
Prelude Therapeutics Incorporated
$3.72HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
RNAC
Cartesian Therapeutics, Inc.
$6.94HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Total return — PRLD vs RNAC
growth of $100 · dividends reinvested · last 6yPRLD -85.6% (-27.6%/yr)RNAC -90.2% (-32.1%/yr)PRLD compounded faster over this window
PRLD RNAC
PRLD vs RNAC: by the numbers
- •PRLD is the larger company ($212M vs $204M market cap).
- •Both run net losses; PRLD's is the smaller (-269.75% vs -10422.48% net margin).
Metrics side by side
Valuation
| Metric | PRLD | RNAC |
|---|---|---|
| P/S ratio | 9.44 | 138.06 |
| P/B ratio | 1.58 | N/A |
Profitability
| Metric | PRLD | RNAC |
|---|---|---|
| Gross margin | 85.91% | 100.00% |
| Operating margin | -861.33% | -3099.93% |
| Net margin | -269.75% | -10422.48% |
| ROE | -45.23% | N/A |
| ROIC | -43.74% | -33.10% |
Growth (annualized)
| Metric | PRLD | RNAC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -50.01% |
| Total return CAGR (5Y) | -33.98% | -44.03% |
Frequently asked
- How have PRLD and RNAC total returns compared?
- Over the past 5 years, PRLD delivered -33.98% and RNAC delivered -44.03% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.